Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Dosing: Geriatric Patients01:15

Drug Dosing: Geriatric Patients

395
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
395
Pharmacodynamics in Geriatric Patients: Effects of Age01:27

Pharmacodynamics in Geriatric Patients: Effects of Age

367
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
367
Drug Toxicity: Risk factors01:24

Drug Toxicity: Risk factors

229
Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...
229
Dementia01:30

Dementia

687
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
687
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

21
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
21
Dementia l: Introduction01:22

Dementia l: Introduction

35
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
35

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Multimorbidity Clusters Among People Aged 65 Years and Over in Australia: A Nationwide Cross-Sectional Data Linkage Study.

The Medical journal of Australia·2026
Same author

What Is Inclusive Occupational Therapy for People Living With Dementia? Lessons From Collaborative Workshops With Diverse Communities.

Australasian journal on ageing·2026
Same author

Language and communication disorders in dementia with Lewy bodies versus Alzheimer's disease: Objective screening and subjective perspectives of patients, their caregivers and clinicians.

Journal of Alzheimer's disease : JAD·2026
Same author

Real-World Comparative Effectiveness and Safety of Immune Checkpoint Inhibitors in Advanced Renal Cell Carcinoma: A Systematic Review.

Targeted oncology·2026
Same author

Proxy reports on the EQ-5D-5L in residential aged care facilities: a validation study.

Health and quality of life outcomes·2026
Same author

SAGE (safer analgesia): a protocol for a pragmatic cluster randomised controlled trial to reduce the use of high-risk medicines in people with chronic back and/or neck pain.

BMJ open·2026

Related Experiment Video

Updated: May 5, 2026

Development of a Virtual Reality Assessment of Everyday Living Skills
10:32

Development of a Virtual Reality Assessment of Everyday Living Skills

Published on: April 24, 2014

20.2K

Multiple Adverse Outcomes Associated with Risperidone in People with Dementia: An Individual Participant Data

Hieu T Le1, Edward C Y Lau1, Christine Y Lu1,2,3

  • 1Faculty of Medicine and Health, School of Pharmacy, The University of Sydney, Pharmacy and Bank Building A15, Science Road, Camperdown, Sydney, NSW, 2006, Australia.

CNS Drugs
|March 3, 2026
PubMed
Summary

Risperidone use in dementia patients increases risks for cerebrovascular and cardiovascular events, particularly after four weeks of treatment. Identifying high-risk individuals is crucial for safer prescribing and minimizing adverse outcomes.

More Related Videos

Generalized Psychophysiological Interaction PPI Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease
09:38

Generalized Psychophysiological Interaction PPI Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease

Published on: November 14, 2017

14.4K
Using Retinal Imaging to Study Dementia
09:17

Using Retinal Imaging to Study Dementia

Published on: November 7, 2017

21.1K

Related Experiment Videos

Last Updated: May 5, 2026

Development of a Virtual Reality Assessment of Everyday Living Skills
10:32

Development of a Virtual Reality Assessment of Everyday Living Skills

Published on: April 24, 2014

20.2K
Generalized Psychophysiological Interaction PPI Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease
09:38

Generalized Psychophysiological Interaction PPI Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease

Published on: November 14, 2017

14.4K
Using Retinal Imaging to Study Dementia
09:17

Using Retinal Imaging to Study Dementia

Published on: November 7, 2017

21.1K

Area of Science:

  • Geriatric Psychiatry
  • Clinical Pharmacology
  • Neuroscience

Background:

  • Risperidone shows limited efficacy for behavioral and psychological symptoms of dementia (BPSD).
  • Current guidelines recommend short-term use (12-16 weeks) due to adverse events.
  • There is a need to understand long-term risks and predictors of adverse outcomes.

Purpose of the Study:

  • To evaluate adverse outcomes associated with risperidone over time in dementia patients.
  • To identify key predictors of these adverse events.
  • To examine high-risk subgroups for safer prescribing strategies.

Main Methods:

  • A meta-analysis of individual participant data from six randomized controlled trials.
  • Included 1009 patients on risperidone and 712 on placebo.
  • Utilized mixed-effect models to analyze adverse outcomes, predictors, and subgroup differences.

Main Results:

  • Risperidone significantly increased risks of cerebrovascular (HR 4.11) and major cardiovascular events (HR 2.00), with median onset around 4-5 weeks.
  • Somnolence was consistent; upper respiratory infections (OR 2.31) and extrapyramidal symptoms (OR 2.93) emerged after week 4.
  • Older age, male sex, and baseline cardiac medication predicted serious adverse outcomes.

Conclusions:

  • Most adverse effects of risperidone in dementia manifest after four weeks of treatment.
  • Assessing baseline risk factors is essential for mitigating harm.
  • Individualized prescribing, potentially guided by risk-benefit calculators, is recommended.